Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research


Kinaxo Biotechnologies said this week it has entered a second collaboration with Takeda Pharmaceutical under which it will apply its quantitative phosphoproteomics platform PhosphoScout to drug development.

The companies' first collaboration, which they signed in 2008, involved use of Kinaxo's KinaTor chemical proteomics technology (GWDN 04/18/2008).

PhosphoScout is an LC-MS/MS based system using strong cationic exchange chromatography in combination with IMAC or TiO2 for phosphopeptide enrichment on the front end and the MaxQuant quantitative proteomics software developed in the lab of Max Planck Institute researcher Matthias Mann.

According to Kinaxo's website, the platform can measure the relative quantity of more than 15,000 phosphorylation sites in a single experiment. The company does its mass spec work on Thermo Fisher Scientific LTQ Orbitrap Velos machines.

In addition to the Takeda collaboration, Kinaxo has struck deals with other global pharma companies including AstraZeneca, Johnson & Johnson, Dalichi-Sankyo, Roche, and Bristol-Myers Squibb.

In February, drug developer Evotec announced it had signed a definitive agreement to purchase Kinaxo for up to €16 million ($22 million) in a cash and stock deal (GWDN 02/09/2011).

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.